Visualizing cells after editing specific genes can help scientists learn new details about the function of those genes. But ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

With an estimated 1.5 lakh cases of oral cancer diagnosed annually in India and a high mortality rate due to late detection, ...

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...